Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

Key Points

• Theravance Biopharma experienced a 25.3% increase in short interest from August 15 to August 31, reaching 4,460,000 shares.
• The company's stock has been upgraded to a "strong-buy" rating by several analysts, with a consensus target price of $23.00.
• Hedge funds have significantly increased their positions in Theravance Biopharma, with institutional investors now owning 99.10% of the company’s stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) was the target of a large growth in short interest in August. As of August 31st, there was short interest totaling 4,460,000 shares, a growth of 25.3% from the August 15th total of 3,560,000 shares. Approximately 9.6% of the company's stock are short sold. Based on an average trading volume of 333,700 shares, the days-to-cover ratio is currently 13.4 days. Based on an average trading volume of 333,700 shares, the days-to-cover ratio is currently 13.4 days. Approximately 9.6% of the company's stock are short sold.

Theravance Biopharma Stock Down 4.1%

Theravance Biopharma stock traded down $0.59 during midday trading on Friday, reaching $13.88. The company's stock had a trading volume of 465,356 shares, compared to its average volume of 508,645. Theravance Biopharma has a fifty-two week low of $7.88 and a fifty-two week high of $14.55. The company has a market cap of $699.00 million, a P/E ratio of 57.83 and a beta of 0.05. The business has a 50-day simple moving average of $12.67 and a 200-day simple moving average of $10.76.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares of the company's stock, valued at $3,723,596.02. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is owned by insiders.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. Nuveen LLC acquired a new position in Theravance Biopharma in the 1st quarter valued at about $3,348,000. Jefferies Financial Group Inc. boosted its stake in shares of Theravance Biopharma by 1,191.9% during the 2nd quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock worth $3,054,000 after acquiring an additional 255,455 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Theravance Biopharma by 121,993.7% during the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Theravance Biopharma by 80.2% during the 2nd quarter. Qube Research & Technologies Ltd now owns 205,280 shares of the biopharmaceutical company's stock worth $2,264,000 after purchasing an additional 91,341 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Theravance Biopharma by 30.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 387,472 shares of the biopharmaceutical company's stock valued at $4,274,000 after acquiring an additional 91,300 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on TBPH shares. Zacks Research cut Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th. B. Riley initiated coverage on Theravance Biopharma in a research note on Friday, September 12th. They set a "buy" rating and a $28.00 price objective for the company. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. BTIG Research raised their target price on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Finally, Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research note on Tuesday, June 17th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $23.00.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.